The Myofibroblast Is the Predominant Plasminogen Activator Inhibitor-1-Expressing Cell Type in Human Breast Carcinomas

This publication has 65 references indexed in Scilit:

• Both u‐PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis
  International Journal of Cancer, 2002
• New functions for the matrix metalloproteinases in cancer progression
  Nature Reviews Cancer, 2002
• Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization
  The FASEB Journal, 2001
• Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and α2-macroglobulin receptor in human breast carcinomas
  International Journal of Cancer, 1996
• Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: An immunohistochemical comparison of normal, benign, and malignant breast tissues
  Cancer, 1996
• Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.
  Journal of Clinical Investigation, 1995
• The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells.
  Journal of Clinical Investigation, 1995
• Type‐1 inhibitor of plasminogen activators
  FEBS Letters, 1991
• Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast Cancer
  Seminars in Thrombosis and Hemostasis, 1991
• Monoclonal antibody mapping of keratins 8 and 17 and of vimentin in normal human mammary gland, benign tumors, dysplasias and breast cancer
  International Journal of Cancer, 1988